Entero Therapeutics, Inc. financial data

Symbol
ENTO on Nasdaq
Industry
Pharmaceutical Preparations
Location
777 Yamato Road, Suite 502, Boca Raton, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Former names
First Wave BioPharma, Inc. (to 5/16/2024), AzurRx BioPharma, Inc. (to 9/14/2021), BioPharma d'Azur, Inc. (to 4/2/2014)
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 125 % +222%
Debt-to-equity 94.6 %
Return On Equity -103 % -131%
Return On Assets -22.8 % +87.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.03M shares +30.7%
Common Stock, Shares, Outstanding 2.03M shares +30.7%
Entity Public Float 6.7M USD +48.9%
Common Stock, Value, Issued 203 USD +31%
Weighted Average Number of Shares Outstanding, Basic 1.76M shares +1445%
Weighted Average Number of Shares Outstanding, Diluted 14.5M shares +12626%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.24M USD -17.9%
General and Administrative Expense 16.7M USD +62.4%
Operating Income (Loss) -20.9M USD -184%
Nonoperating Income (Expense) -82.6K USD +95.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.29M USD -128%
Income Tax Expense (Benefit) -14.9M USD
Net Income (Loss) Attributable to Parent -6.16M USD +32.1%
Earnings Per Share, Basic -8.3 USD/shares +97.4%
Earnings Per Share, Diluted -11 USD/shares +96.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.43M USD +66.2%
Accounts Receivable, after Allowance for Credit Loss, Current 20K USD -28.7%
Assets, Current 7.49M USD +112%
Property, Plant and Equipment, Net 25.7K USD -29.5%
Operating Lease, Right-of-Use Asset 181K USD -25.6%
Intangible Assets, Net (Excluding Goodwill) 63.4M USD
Goodwill 20M USD +1090%
Assets 91.1M USD +1547%
Accounts Payable, Current 2M USD +325%
Accrued Liabilities, Current 2.55M USD +202%
Liabilities, Current 6.17M USD +135%
Deferred Income Tax Liabilities, Net 571K USD
Operating Lease, Liability, Noncurrent 128K USD -35.1%
Other Liabilities, Noncurrent 3.85M USD +58528%
Liabilities 13.3M USD +370%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.45M USD -14.8%
Retained Earnings (Accumulated Deficit) -179M USD -3.57%
Stockholders' Equity Attributable to Parent 16.2M USD +497%
Liabilities and Equity 91.1M USD +1547%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.75M USD -31.7%
Net Cash Provided by (Used in) Financing Activities 3.38M USD -4.74%
Net Cash Provided by (Used in) Investing Activities 88.2K USD
Common Stock, Shares Authorized 100M shares +100%
Common Stock, Shares, Issued 2.03M shares +30.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 22K USD +144%
Deferred Tax Assets, Valuation Allowance 33.4M USD +13.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 1.6 pure
Deferred Tax Assets, Gross 33.5M USD +13.4%
Operating Lease, Liability 199K USD -24.8%
Depreciation 7.78K USD +6.56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.8M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid 217K USD -27.5%
Property, Plant and Equipment, Gross 107K USD +21.6%
Operating Lease, Liability, Current 71.2K USD +4.83%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60.6K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 88.8K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17.9K USD -47.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 60.6K USD -31.8%
Deferred Tax Assets, Operating Loss Carryforwards 23.1M USD +22%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 60.6K USD -31.8%
Additional Paid in Capital 195M USD +11.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 34K USD +17.1%
Deferred Tax Assets, Net of Valuation Allowance 48K USD -25%
Share-based Payment Arrangement, Expense 954K USD +4.87%
Interest Expense 79.7K USD +314%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%